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Background: Home self-administration of misoprostol for medical abortion has been 
suggested as safe, efficient, feasible and acceptable. However, it remains inaccessible for many 
women especially in low-resource settings. Administration of misoprostol at home and self-
assessment by urine pregnancy tests (UPTs) to confirm complete termination of pregnancy with 
follow-up by home visits or telephone call after 12-15 days after the intake of mifepristone 
helps to de-medicalize abortion and provides privacy to women. 
 
Objective: To assess the effectiveness, safety, and acceptability of self-assessment of the 
outcome of medical abortion in a non-inferiority comparison with routine clinic follow-up after 
medical abortion at home. 
 
Methodology: A systematic review for randomized controlled trials (RCTs) of self-assessment 
of the outcome of medical abortion compared with routine clinic follow-up was conducted. The 
systematic review followed the Cochrane Handbook of Systematic Reviews for Intervention. 
A thorough search was performed in databases such as Medline, Embase, Cochrane Central 
Register of Controlled Trials (CENTRAL), Web of Science, CINAHL, British Nursing Index 
and Archive, Scopus and Google Scholar. Searches were also done in ClinicalTrials.Gov and 
WHO-ICTRP for ongoing studies.  
 
The population was women of reproductive age, 15 years or above, who had a confirmed 
pregnancy and who had requested a medical termination of pregnancy up to 9 weeks (63 days) 
of gestation age, which they performed at home. The intervention, self-assessment of outcome 
done by UPTs by women themselves at home combined with a follow-up by telephone call or 
home visit to confirm the complete termination of pregnancy, was compared with assessment 
of the outcome of medical abortion performed by medical/health care personnel during routine 
clinic follow-up visits. The primary outcome was effectiveness of self-assessment of the 
outcome of medical abortion compared to routine clinic follow-up, while its safety and 
acceptability were the secondary outcomes. 
 
Risk of bias (RoB) assessment was performed for each included RCT in accordance with the 




analysed as risk ratios (RR) with 95% confidence intervals (CI). Review Manager 5.3 (RevMan 
2014) was used to pool the data (meta-analysis) and to generate forest plots to display the 
results. A GRADE (Grading of Recommendations Assessment, Development, and Evaluation) 
assessment was conducted to assess the certainty of the evidence. 
 
Results: Four studies met the inclusion criteria (n = 5394 participants). All were RCTs, two of 
these were non-inferiority RCTs, which described the results of self-assessment of the outcome 
of induced abortion with mifepristone and misoprostol at home. The studies were conducted in 
low to high resource setting countries. There was low risk of bias associated with the included 
studies. Pooled analyses from all studies showed no statistically significant difference in 
complete abortion rates between self-assessment and routine clinic follow-up: RR= 1.00; 95% 
CI = 0.99 to 1.01 (high quality evidence). The point estimates for the pooled safety measures 
were: need for surgery (RR= 0.92; 95% CI = 0.7 to 1.21), occurrence of haemorrhage (RR= 
1.48; 95% CI = 0.84 to 2.60), occurrence of fever and infection (RR= 0.41; 95% CI = 0.08 to 
2.12), and drug administration for haemorrhage (RR= 1.81; 95% CI = 0.61 to 5.35). There were 
no statistically significant differences between the groups with respect to safety of the 
assessment technique (moderate to low quality evidence). The results showed that the 
preference of follow-up method is significantly greater for self-assessment compared to routine 
clinic follow-up. Overall, these results show that self-assessment at home is as safe as routine 
clinic follow-up. 
 
Author’s Conclusions: This systematic review summarizes and presents that there is high 
quality evidence that the effectiveness of self-assessment of the outcome of medical abortion 
at home is not inferior to routine clinic follow-up. Further, it shows that self-assessment with 
telephone or home follow-up is safe and acceptable compared to routine clinic follow-up. This 
intervention is feasible to implement. Therefore, it can be incorporated as an alternative to 
abortion services in both low and high resource settings, giving women a choice whether to do 
the assessment by themselves or in clinics. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background 
The termination of pregnancy by removing fetus or embryo before it can survive outside the 
uterus is called ‘abortion’ (1). The two main types of induced abortion are surgical abortion and 
medical abortion. Surgical abortion is the method that involves the contents of pregnancy being 
removed vaginally from the uterus by an experienced doctor or clinician with or without the 
use of anaesthesia (2). Medical abortion is the use of abortifacient pharmaceutical drugs (3-5). 
In 1988, medical abortion with mifepristone and prostaglandin was first introduced (6). The 
anti-progesterone mifepristone in combination with a prostaglandin analogue, was licensed for 
ending the pregnancy up to 63 days (9 weeks) of gestation in 1991 (7). Medical abortion has 
three different methods: the drug mifepristone followed by misoprostol, the drug methotrexate 
followed by misoprostol, and misoprostol alone. The World Health Organization (WHO) 
recommends the mifepristone-misoprostol combination regimen for medical abortion (8, 9). 
The mifepristone-misoprostol regimen works faster and is more effective at later gestational 
ages than the other regimens (10).  
Medical abortion using mifepristone, followed 24-48 hours later by buccal or vaginal 
misoprostol is considered to be more effective than even surgical abortion (vacuum aspiration), 
in case of early abortions, i.e., up to 49 days of gestational age, particularly when detailed 
inspection of aspirated tissue is not included in the clinical practice (11). The mifepristone-
misoprostol combination regimen is approximately 98% effective up to 9 weeks gestational age 
(12). For the past 25 years, mifepristone-misoprostol is considered safe and acceptable because 
this method is simple, requires fewer resources than surgical abortion and provides women with 
a choice of intervention (13). The procedure can be done either at a clinic or at home (14). A 
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systematic review performed by Ngo et.al. in 2011 concluded that home-based medical abortion 
is safe and there are no differences in effectiveness or acceptability between home-based and 
clinic-based medical abortion across countries (15). 
Follow-up, be it after medical abortion or surgical abortion should provide individualized care 
(16). Women having an early medical abortion require follow-up to confirm complete and 
successful termination of pregnancy. In general, follow-up after medical abortion is done by an 
ultrasound examination (17). Routine follow-up includes ultrasonography, measurement of 
human chorionic gonadotropin (hCG) in serum or urine, and pelvic examination. This can 
involve more than one clinical visit (13). An alternative method of detecting ongoing pregnancy 
after medical abortion at home includes measurement of urine hCG by pregnancy tests kits, 
either alone or in combination with questions about bleeding and symptoms of pregnancy (14, 
17). Pregnancy tests determine pregnancy by detecting the hormone hCG in women’s urine. 
Test sensitivity is the hCG threshold at which point a positive result is indicated. There are 
different test sensitivity pregnancy test kits such as low sensitivity urine pregnancy test 
(LSUPT), semi-quantitative urine pregnancy test (SQUPT), or high-sensitivity pregnancy test 
(HSPT); the lower the threshold, the higher the test sensitivity (14, 18). To select the best test 
among the home pregnancy tests, three major factors should be taken into considerations: test 
sensitivity, the ease of use/interpretation, and price (18). Recently, studies have shown that the 
self-assessment of outcome of medical abortion done by urine pregnancy test (UPT) kits with 
a follow-up telephone call, text message, or online can be an alternative method of clinical 
follow-up after medical abortion. A study has shown that a telephone follow-up with self-test 
is a feasible and accurate method of determining the outcome after medical abortion (14, 17). 
In Britain (19), France (20), Switzerland (21), and the Nordic countries (22), early medical 
abortions account for the majority of abortions before 9 weeks of gestational age, while in the 
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United States, the percentage of early medical abortions is lower (23, 24). In 2015, the 
percentage of medical abortion in Scotland, Norway, and Sweden accounted for 81%, 86%, and 
91% respectively. In Finland, early medical abortion accounted for 95% of all medical abortion 
in 2014. The rates for England and Wales were 55% and in Switzerland it was 70% in the year 
2015, while the rate was 58% in France in 2013 and only 23% in the United States in 2011 (25). 
1.2 Description of the condition (problem) 
It is estimated that worldwide, in every 1000 women in the age group 15-44 years, 
approximately 35 abortions occurred annually in the years 2010-14. With the increase in the 
population, the annual number of abortions also globally increased by 5.9 million from the 
years 1990-1994 to 2010-14 (26). Worldwide, approximately 56 million abortions occur each 
year (26), of which almost half is done unsafely (27). Unsafe abortions cause around 47,000 
deaths and 5 million hospital admissions each year. The health risk of abortion principally 
depends on whether it is performed safely or unsafely (28). Studies show that induced abortions 
can decrease the risk of long-term mental or physical problems when they are performed legally 
and safely (28, 29). The WHO recommends that legal and safe abortions should be available to 
all women (30). Legality of abortion often favors that a woman has the right to make her own 
decisions about her own body (31). 
Despite the fact that early first trimester medical abortion is a safe and effective method for 
induced abortion, the procedure still remains inaccessible for many women in low-resource 
settings. Consequently, this reduces access to safe abortion and leads women to seek unsafe 
abortion. Globally, unsafe abortion is an important cause of maternal mortality. In India alone, 
8% of maternal deaths is caused by unsafe abortion (14). Worldwide, it is estimated that 7.9% 
of all maternal deaths is due to abortion. Even in areas where induced abortion is legal, because 
of religious beliefs and cultural perceptions, women are likely not to disclose the abortion 
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attempts and their relatives or health personnel do not report deaths related to it. Thus, the fact 
that abortion related deaths are under-reported might lead to under-estimation of the death rates. 
This means that apart from the estimation done, there might be some increase in the abortion 
related death rates (32). 
As stated, the main purpose of a routine follow-up visit after medical abortion is to ensure the 
termination of pregnancy. The number of routine clinic follow-up visits required in medical 
abortion is one of the most important barriers affecting access and acceptability of medical 
abortion, because the clinic visit is perceived as burdensome for women with low autonomy 
and limited financial resources. Furthermore, for many women, the long travel time required 
for clinic visits results in lost wages and difficulties in ensuring privacy (14).  
1.3 Description of the intervention 
In the mifepristone-misoprostol combination regimen, the intake of mifepristone orally (200 
mg) is followed by use of misoprostol (800mcg) within 48 hours, either at clinic or at home 
(14). Administration of misoprostol at home aids to de-medicalize abortion and provides 
privacy to women (13). The route of misoprostol administration might be sublingual, vaginal 
or oral, differing across clinics according to their standard protocols (14). An assessment is 
required to confirm the outcome of the medical abortion. The primary outcome is complete 
termination of pregnancy without the need for additional clinical intervention within 30 days. 
The assessment can be performed by health personnel at a clinic or be self-assessed. Self-
assessment of the outcome at home is done with a UPT, typically LSUPT, SQUPT, or HSPT. 
One of the most important reasons for the use of a UPT after medical abortion is to recognize 
if there is any cases of ongoing pregnancy which might go undetected in the absence of routine 
clinic follow-up (33). For self-assessment of the outcome, women are provided with a UPT and 
the assessment is to be done 10-14 days after the intake of mifepristone. They are provided with 
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detailed instructions at the clinic on how to use the test kit and asked to seek assistance with 
clinical personnel if they encounter any health problems or a positive or an unclear test result. 
Follow-up of women to screen for pregnancy continuation or complications is done by home 
visits, telephone call, text message or online 12-15 days after intake of mifepristone (14).  
1.4 How the intervention might work 
Home self-administration of misoprostol for medical abortion has been suggested as safe, 
efficient, feasible and acceptable by a handful of studies from the United States (34-38). 
Administrating medical abortion at home allows the women to carry out abortion in a more 
familiar environment, allows more privacy, and therefore avoids the inconvenience and reduces 
the cost of the additional clinical visits. Studies have shown it to be highly acceptable and the 
majority of women specified that they would prefer home administration of medical abortion 
again in the hypothetical situation of needing another abortion (7). Women reported that it is 
much easier to tolerate the side effects in the known, comfortable environment of their homes 
with someone familiar nearby to support them, which ultimately prepare them for any problems 
that could arise later (39).  
The Royal College of Obstetricians and Gynaecologists in its recent guidance has advised that 
telephone follow-up and urine pregnancy testing method may be considered appropriate in the 
absence of evidence to recommend one particular procedure for routine follow-up to exclude 
ongoing pregnancy after medical abortion (17). Further, home pregnancy tests with different 
sensitivity levels are easy to use and interpret. These are easily available commercially in the 
market at an affordable price. In addition, these tests are very accurate exhibiting over 99% 
accuracy, if done in clinical settings. However, the accuracy rate depends on how correctly it 
is performed and interpreted (18). Various health professionals consider a routine ultrasound 
superior to self-assessment with LSUPT in combination with a telephone follow-up to identify 
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the outcome of medical abortion, and state that the latter is only suitable for low-resource 
settings (17). However, the study done by Cameron et al. showed that, both in theory and 
practice, a telephone follow-up was a popular choice for women. It showed that more than three 
out of four women elected to consult via telephone follow-up rather than to re-attend the clinic 
for a routine ultrasound. The main reason was to avoid another trip to the hospital and this 
follow-up method was convenient and satisfactory (17). 
1.5 Why is it important to do this review 
Health care providers, researchers, and policy makers need to update the existing knowledge 
and information they have regularly. Systematic reviews efficiently incorporate prevailing 
information and provide data for rational decision making eventually managing the inundated 
amounts of information within the health system. Additionally, meta-analyses can increase 
power and precision of estimates of treatment effects and exposure risks, improving the 
reliability and accuracy of conclusions (40). 
Grossman et al. in their review in 2010 stated that the alternative techniques such as women’s 
self-assessment without using any tests, clinician’s assessment, serum hCG measurements, 
urine pregnancy testing or a combination of these techniques to routine in-person follow-up 
visits after medical abortion are accurate at diagnosing the primary outcome (complete 
termination of pregnancy) of medical abortion. However, the researchers added that there is a 
need for additional research to determine the accuracy, acceptability, and feasibility of 
alternative follow-up modalities in practice, particularly of home-based urine testing with self-
assessment (41).  
Furthermore, recently, a number of studies including randomized controlled trials (RCTs) have 
been conducted, comparing the self-assessment of outcome of medical abortion with clinic 
follow-up visits (13, 14). These might generate new facts and/or provide stronger evidence to 
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support the prevailing knowledge. Therefore, this systematic review can be expected to refine 
and add to the existing information of home-based self-assessment of the outcome of medical 
abortion compared to routine clinic follow-up visits.  
1.6 Review question 
Is self-assessment of the outcome of medical abortion at home comparable to assessment 
performed by medical/health care personnel during a routine clinic follow-up in terms of 
effectiveness, safety, and acceptability? 
1.7 Objective 
The objective of this systematic review was to assess the effectiveness, safety, and acceptability 
of self-assessment of the outcome of medical abortion in a non-inferiority comparison with 


















CHAPTER 2: METHODOLOGY 
 
It is recommended by the Cochrane Organization that systematic reviews should have at least 
two reviewers involved at its various steps to reduce the risk of bias (RoB) (42). Therefore, for 
this systematic review, two persons were involved in selection of studies, data extraction, 
assessment of RoB of the included studies, and the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) assessment. However, since this is a thesis work, 
beside the main author, other persons who were involved in various steps have no contribution 
to the main contents of the thesis. The study protocol is registered in PROSPERO (Reference 
no.: 2017: CRD42017055316) (43). 
2.1 Search Strategy 
The main author conducted literature searches in the following databases: Medline, Embase, 
Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), British Nursing Index and Archive, 
Scopus and Google Scholar. Searches were also done in ClinicalTrials.Gov and World Health 
Organization’s International Clinical Trials Registry Platform (WHO-ICTRP) for ongoing 
studies. 
The reference lists of systematic reviews, literature reviews, and other relevant publications 
were manually checked to identify relevant studies that were not covered by the database 
searches. 
Medical abortion with mifepristone and prostaglandin was first introduced in the year 1988 (6), 




(7). Therefore, the databases were searched only from the year 1991 to the mid of February 
2017. In addition, the searches were filtered to identify human studies. 
The sets of search terms combined were terms for — Abortion AND Pregnancy Test AND 
Home (for details, see Appendix 1). 
The search strategy was drafted by the main author and reviewed by the supervisor and the co-
supervisor. The strategy was first tested, revised, and then finalized by search librarians from 
University of Tromsø (UiT)-The Arctic University of Norway and Norwegian Institute of 
Public Health (NIPH). The finalized strategy was then used for the searches.  
Auto alert for new searches in databases like Cochrane library and Web of science was done 
for almost a month after the first search. It was then stopped to continue into the next steps of 
the review.  
2.2 Selection of literature 
All the searches in the databases were imported to Endnote X7.2, a software tool to manage 
bibliographies. The duplicates were removed. Two reviewers screened the titles and abstracts 
of all records identified by the search, first independently then jointly. All records that were 
considered relevant were promoted to full text screening. The main author obtained these 
articles in full text. Two reviewers assessed all the relevant studies in full text, independently 
and then jointly. These full text papers were examined for inclusion based on the criteria stated 
below. Reasons for exclusion of full texts were recorded.  
If there were any doubts on inclusion of a study, they were documented and the doubts were 
resolved by discussion with the supervisor and the co-supervisor. The study protocol mentioned 




clarification (43). However, this situation did not arise; therefore, none of the authors were 
contacted.  
2.3 Inclusion and exclusion criteria 
The inclusion and exclusion criteria for this systematic review are described below: 
2.3.1 Study design 
RCTs and non-randomized controlled trials (non-RCTs), interrupted-time-series, controlled 
before-and-after studies, and prospective cohort studies with a control group were eligible for 
inclusion. The study protocol mentioned that in the event that several RCTs of moderate to high 
methodological quality were identified, only including RCTs would be considered (43). Those 
studies where the outcome data were collected retrospectively were excluded.  
2.3.2 Population 
Women of reproductive age (15 years or above) who had a confirmed pregnancy, the 
confirmation of which was done by ultrasound, clinically or by a positive urine or serum hCG, 
and who requested a medical termination of pregnancy of up to 9 weeks (63 days) of gestation 
period, which they performed at home. 
2.3.3 Intervention 
Self-assessment of the outcome of medical abortion at home. The self-assessment done by 
UPTs such a LSUPT, SQUPT, or HSPT by women themselves at home with a follow-up by 
home visit, telephone call, text message, or online or a combination of these to confirm the 
complete termination of pregnancy.  
2.3.4 Comparison 
Assessment of the outcome of medical abortion at home performed by medical/health care 





The primary outcome was the percentage of women with successful complete abortions, i.e., 
complete evacuation of the uterine contents with no requirement for surgery or any medical 
intervention within 3 months of complete abortion.  
The secondary outcomes were side effects and complications, such as pain, haemorrhage 
(excessive bleeding), endometritis, gastrointestinal side effects (e.g., nausea, vomiting, 
diarrhoea), headache, dizziness, and thermoregulatory changes; loss to follow-up; number of 
clinic visits and number of telephone consultations; and acceptability. 
2.3.6 Others 
Only papers written in English language were included. The databases were searched only from 
the year 1991 to present. 
Clinical practice guidelines, conference abstracts and proceedings, books, chapters, animal and 
modelling studies, reviews and publications containing only qualitative information were 
excluded.  
2.4 Assessment of methodological quality (Risk of bias assessment) 
Two reviewers assessed RoB, independently, and then jointly. RoB was assessed for each 
included RCT in accordance with the criteria in the Cochrane Handbook for Systematic 
Reviews of Interventions (42). The following key domains were used to assess RoB: sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of outcome 
assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. 
Response options of ‘Low Risk’, ‘Unclear Risk’, and ‘High Risk’ for each of the domains were 




could not be made, the risk was assigned as unclear RoB, and procedures with cause for concern 
were assigned as high RoB (42).  
The study protocol mentioned that in the event that other designs than RCTs were included, the 
Cochrane Effective Practice and Organization of Care (EPOC) group’s checklist for non-RCTs 
(44) would be used (43). However, the study design of all the studies selected were RCTs, 
therefore, the Cochrane EPOC checklist was not used.   
Any disagreements between the two reviewers were resolved by discussion with the supervisor. 
2.5 Extraction of data 
The main author extracted data from the included studies onto a standard simple Excel sheet 
using a pre-designed data recording form. A second person then checked the completeness and 
accuracy of the data extraction for all included studies. Any differences were discussed until 
consensus was reached.  
The following core data were extracted from all included studies: 
 Title, authors, and other publication details 
 Study design and aim 
 Setting (place and time of recruitment/data collection) 
 Sample characteristics (age, gender, ethnicity, education etc.) 
 Intervention characteristics (type of self-assessment, type of follow-up) 
 Methods of outcome measurement (clinical, self-report, etc.) 
 Results related to the outcomes (successful complete abortions, side effects and 





2.6 Data analysis 
Data were summarized and presented narratively in text and tables for each comparison. The 
study protocol specified that for continuous data, the group post-test means and standard 
deviations would be used to calculate effect sizes using Review Manager 5.3 (RevMan 2014) 
software. When possible, the effect sizes would be expressed in the form of mean differences 
(MD) and 95% confidence interval (CI), but when different scales were used to measure the 
same outcome, standardized mean differences (SMD) with corresponding 95% CI would be 
calculated (43). However, none of the outcomes were presented as continuous data. All 
outcome were dichotomous. Dichotomous data were analysed as risk ratios (RR) with 95% CI.  
For the reason that the included studies were sufficiently similar – similar Population, 
Intervention, Comparison, Outcome (PICO) – to pool the results, meta-analyses was performed 
of the included study outcomes. Review Manager 5.3 (RevMan 2014) was used to pool the data 
(meta-analyses) and to generate forest plots to display the results.  
The certainty of the evidence for the primary outcome and secondary outcomes was assessed 
with the GRADE tool. GRADE is a method for assessing the certainty of the evidence in 
systematic reviews. Evidence from RCTs start as high certainty evidence but may be 
downgraded depending on five criteria: i) methodological study quality as assessed by review 
authors, ii) degree of inconsistency, iii) indirectness, iv) imprecision, and v) publication bias. 
Evidence from observational studies start as low certainty evidence but may be upgraded. 
Upgrading of results from observational studies is possible according to GRADE if there is a 
large effect estimate, a dose-response gradient, or if all possible confounders would only 
diminish the observed effect and that therefore the actual effect most likely is larger than what 




 High quality: We are very confident that the estimate of the effect lies close to the true 
effect. This means that further research is very unlikely to change our confidence in the 
estimate of effect. 
 Moderate quality: We are moderately confident in the estimate of effect. Although the 
true effect is likely to be close to the effect estimate, there might be a possibility that it 
is substantially different. This means that further research is likely to have an important 
impact on our confidence in the estimate of effect and may change the estimate. 
 Low quality: We have limited confidence in the estimate of effect because the true 
effect may be substantially different from the effect estimate. This means that further 
research is very likely to have an important impact on our confidence in the estimate of 
effect and is likely to change the estimate. 
 Very low quality: We have very little confidence in the estimate of effect because the 
true effect is likely to be substantially different from the effect estimate. This means that 
we are very uncertain about the estimate. 
GRADE assessment was performed for the primary outcome and some of the secondary 














CHAPTER 3: RESULTS 
 
3.1 Results of the search 
There were 831 hits from the database searches in Medline, Embase, CENTRAL, Web of 
Science, CINAHL, British Nursing Index and Archive, Scopus, ClinicalTrials.Gov and WHO-
ICTRP (For details, see Appendix 2). Only the first 200 hits were selected from the Google 
Scholar search because there were more than 8000 hits, which were not possible to include in 
this thesis work. Thus, in total, 1,031 citations were identified from the database searches. From 
the reference lists of systematic reviews, literature reviews, and other relevant publications that 
were manually checked 38 citations were selected for the preliminary screening. After 
removing the duplicates from these citations, 877 remained. Titles and abstracts of all the 877 
papers were screened. Among these, 755 records were discarded because they clearly did not 
meet the inclusion criteria. The full texts of the remaining 122 records were screened in more 
detail. Of these records, 117 records were excluded. The reasons for exclusion were recorded 
(For details, see Appendix 3). The most common reasons for exclusion were: the intervention 
did not match the inclusion criteria, the outcomes were not relevant, the study design did not 
match, and many were conference abstract presentations. In clinicaltrials.gov, three studies 
were completed but their results were not published yet, two studies are in progress as they are 
just recruiting the participants, and one study has not yet started. Therefore, these studies could 
not be screened for inclusion. It is possible, but unlikely, that the inclusion of these studies 
would change the results of this systematic review. Consequently, four studies (presented in 




3.2 Description of included studies and their context 
The included studies covered a period of 4 years; they were carried out between the years 2010 
and 2014. All the included studies were published in peer reviewed medical journals: The 
Lancet (13), The Lancet Global Health (14), Contraception (49), Obstetrics and Gynecology 
(47) and PloS one (48). As seen in table 1, the study area of all the studies varied from low-
resource setting to high-resource setting countries: India (14), Vietnam (47), Moldova and 
Uzbekistan (49), and Austria, Finland, Norway, and Sweden (13). The study design of all the 
studies were RCTs, two of these specified their study as a non-inferiority RCT (13, 14). In one 
of the studies, which was done in a low-resource setting, the literacy rate of the enrolled 
participants was 45% only (14). The participants in all the studies were women who were opting 
for medical termination of pregnancies, who had less than or equal to 9 weeks (63 days) of 
gestational age. In the study done by Iyengar et.al., the outcome in the self-assessment group 
was measured by low sensitivity pregnancy test kits and follow-up was done after 2 weeks by 
telephone call or home visit (14). In all the other studies, the outcome in the self-assessment 
group was measured by semi-quantitative pregnancy test kits and follow-up was done after 2-
3 weeks by telephone call. The primary outcome measured in each of the studies was complete 
termination of pregnancy, while the secondary outcome was safety and acceptability of medical 










Table 1: Characteristics of included studies 
(For details, see Appendix 4)  








-Mean Age: 27.1 years 
-Education: 45% literate 
Women above 18 years 
with unwanted 
pregnancies opting for 
medical abortion with 
gestational age 9 weeks 
or less. 
-Self-assessment of outcome 
at home with a LSUPT and 
pictorial instruction sheet. 
-Follow up after 2 weeks by 
home visit or telephone call. 
Routine clinic 
follow up 
Primary Outcome: Complete abortion without continuing 
pregnancy or need for surgical evacuation or additional 
mifepristone and misoprostol. 
 
Secondary Outcomes: Safety (no adverse events and side 
effects) and feasibility of home assessment 
 
Oppegaard 
et. al., 2015 
(13) 
-Study design: RCT (non-
inferiority)  
-Country: Austria, Finland, 
Norway, Sweden 
-N=929 (baseline) 
-Mean Age: 25.97 years 
-Education: Not stated 
Women aged 18 years 
and above who 
requested medical 
termination of 
pregnancy up to 63 days 
of gestational age. 
-Self-assessment of outcome 
at home with a semi-
quantitative urine hCG test  
-Follow up after 1-3 weeks 
by telephone consultation. 
Routine clinic 
follow up 
Primary Outcome: Complete abortion not requiring further 
medical or surgical intervention within 3 months to 
complete abortion 
 
Secondary Outcomes: Clinical efficacy (adverse events and 
complications), loss to follow-up, additional visits, 
additional telephone consultations, acceptability, and 
initiation of agreed contraception. 
Ngoc et. al., 
2014 (47) 
-Study design: RCT  
-Country: Vietnam 
-N=1433 (baseline) 




Women opting for early 
medical abortion with 
gestational age 63 days 
or less. 
 
Self-assessment of outcome 
at home with a SQUPT in 
combination with self-
administered checklist. 




Primary Outcome: Complete abortion without surgical 
evacuation. 
 




-Study design: RCT  
-Country: Moldova & 
Uzbekistan 
-N=2400 (baseline) 
-Median Age: 27 years 
-Education: 100% literate 
 
Women with 
pregnancies less than or 
equal to 63 days of 
gestational age who 
wanted a medical 
abortion. 
Self-assessment of outcome 
at home with a semi-
quantitative pregnancy test in 
combination with symptom 
checklist. 
 




Primary Outcome: Complete abortion without surgical 
evacuation. 
 




The above table shows the general characteristics and PICO of the included studies. For detailed 
information, see ‘Characteristics of included studies’ in Appendix 4. 
3.3 Risk of bias (RoB) assessment of included studies 
This systematic review included four studies based on self-assessment of outcome of medical 
abortion at home where follow-up was done by telephone call or telephone call combined with 
home visit compared to routine clinic follow-up. The study design of all of the included studies 
were RCTs, which means they had consistency in methodological approach. “Performance 
bias” was measured in two different domains: ‘Blinding of participants’ and ‘Blinding of 
personnel’, because the judgements for bias assessment can be different for participants and 
personnel. Similarly, “Detection bias” was measured in three different domains separated for 
each of the major outcomes: effectiveness, safety, and acceptability. This is because the 
judgements for bias assessment can be different for different outcomes.  
The RoB assessment with the judgement and the explanation supporting the judgement for each 
domains is described in more details in the ‘Characteristics of included studies’ (See Appendix 
4) and summarized below. The figures (adapted using Review Manager 5.3 software-RevMan 
2014) below provide graphical summaries of the review authors’ judgements about each RoB 
across the studies presented as percentages (presented in Figure 1) as well as judgement of RoB 





Figure 1: RoB graph: review authors' judgements about each RoB item presented as 
percentages across all included studies. 
 





Random sequence generation and allocation concealment (Selection bias) 
In all the included studies, randomization was done with a computer generated randomization 
sequence and sealed opaque envelopes were used to allocate the participants. Therefore, there 
was low risk of selection bias.  
Blinding of participants and personnel (Performance bias) 
It was not possible to blind the participants (women) and personnel (clinicians) because the 
women themselves were involved in giving intervention (self-assessment) and the clinicians 
were involved in giving counselling to women in the intervention group. The biological 
outcomes (effectiveness and safety) were not likely to be influenced by lack of blinding of 
participants and personnel. However, self-reporting (acceptability) might be influenced by lack 
of blinding of participants but not by personnel. Therefore, there was unclear risk in lack of 
blinding of participants while there was low risk even if there is lack of blinding of personnel. 
Blinding of outcome assessment (Detection bias) 
It was not possible to blind the outcome assessors (the women themselves in the self-assessment 
group and the clinicians in the clinic follow-up group). The biological outcomes (effectiveness 
and safety) were not likely to be influenced by lack of blinding of outcome assessors (both 
women and clinicians). However, self-reporting (acceptability) might be influenced by lack of 
blinding of participants but not by personnel. Thus, there was low risk even if there is lack of 
blinding of outcome assessment for biological outcomes i.e., effectiveness and safety, while 





Incomplete outcome data (Attrition bias) 
There was a low percentage of loss to follow-up in two of the included studies (14, 49). In one 
of the studies, the percentage of loss to follow-up was relatively high (23% in routine follow-
up group and 20% in self-assessment group) but it was not statistically significant in the 
intervention and the control group. Additionally, the analysis was done per protocol and by 
intention-to-treat (ITT) population (13). This means there was low RoB in these studies. 
However, in one of the studies, the difference between the proportions of women who were lost 
to follow-up was statistically significant between the intervention and the control groups. 
However, the percentage of loss to follow-up was low, therefore, there was unclear RoB (47). 
Selective reporting (Reporting bias) 
The published reports of all included studies had all the expected outcomes, including those 
that were pre-specified in the protocols. Therefore, there was low risk of reporting bias in all of 
the four included studies. 
Other biases 
No other biases were detected. Consequently, there was low risk of any other possible biases. 
3.4 Effects of intervention 
In this systematic review, the intervention was self-assessment of the outcome of medical 
abortion at home done by using UPT by women themselves at home with a follow-up by 
telephone call or telephone call combined with home visit. The primary outcome was the 
effectiveness of self-assessment technique, while secondary outcomes were mainly divided into 




Primary outcome: Effectiveness of self-assessment of the outcome of medical abortion at 
home versus routine clinic follow-up. All the four included studies measured complete 
termination of pregnancy. The meta-analyses result of this outcome is shown in figure 3. 
 
Figure 3: Forest plot comparing rates of complete termination of pregnancy among women 
who performed self-assessment of outcome at home and routine clinic follow-up 
The point estimate (RR= 1.00; 95% CI = 0.99 to 1.01) for the pooled effect shows that the 
effectiveness of assessing outcome of medical abortion at home was similar in the self-
assessment group and the routine follow-up group. In addition, there was no heterogeneity 
among the included studies in regard to effectiveness of outcome assessment (I2= 0%). The p-
value of test for overall effect was 0.86, which means there was no statistically significant 
difference between the intervention and control group. Thus, the pooled effect from all the four 
studies showed there is no difference in assessment of complete termination of pregnancy in 
medical abortion whether it is done at home by women themselves or in a routine clinic follow-
up by clinicians.  
In the study done by Iyengar et. al. 2015, the ITT population was used (14). In all the other 




49). In the study done by Oppegaard et. al. 2015, only the risk difference of the ITT population 
was given: -0.8 (95% CI -3.8 to 2.3), which was similar to the risk difference of the evaluable 
population: -1.0 (95% CI -4.0 to 2.0). The data for evaluable population were therefore used in 
the meta-analyses (13). 
Secondary outcome: Safety of assessment of outcome of medical abortion at home versus 
routine clinic follow-up. All the four included studies measured the need for surgery during 
medical abortion at home. The meta-analyses result of this outcome is shown in figure 4. 
 
Figure 4: Forest plot comparing rates for need for surgery during medical abortion at home 
among women who performed self-assessment of outcome at home and routine clinic follow-
up 
The point estimate (RR= 0.92; 95% CI = 0.70 to 1.21) for the pooled effect shows that there 
was 8% lower risk for need for surgery during medical abortion at home in the self-assessment 
group compared to the routine follow-up group. In addition, there was no heterogeneity among 
the included studies in regard to need for surgery (I2= 0%). The p-value of test for overall effect 




and control group. Thus, even though the pooled effect from the four studies showed there is a 
lower risk in the self-assessment group for need for surgery during medical abortion than in the 
routine clinic follow-up group, there is no statistically significant difference between the 
groups.  
In the study done by Iyengar et. al. 2015, the ITT population was used (14). In all the other 
studies, the evaluable population was used (13, 47-49). 
All the four included studies measured the occurrence of haemorrhage (excessive bleeding) 
during medical abortion at home. The meta-analyses result of this outcome is shown in figure 
5. 
 
Figure 5: Forest plot comparing rates for occurrence of haemorrhage (excessive bleeding) 
during medical abortion at home among women who performed self-assessment of outcome at 
home and routine clinic follow-up 
The point estimate (RR= 1.48; 95% CI = 0.84 to 2.60) for the pooled effect shows that there 
was a higher risk of occurrence of haemorrhage (excessive bleeding) during medical abortion 




test for overall effect was 0.17, which means there was not statistically significant different 
between the intervention and control groups. However, there was moderate heterogeneity 
among the included studies concerning occurrence of haemorrhage (I2= 43%). Hence, even 
though the pooled effect from all the included studies showed there is a higher risk in the self-
assessment group for occurrence of haemorrhage (excessive bleeding) during medical abortion 
at home compared to routine clinic follow-up group, there is no statistically significant 
difference between the groups.  
Only two of the included studies measured the occurrence of fever and infection during medical 
abortion at home. The meta-analyses result of this outcome is shown in figure 6. 
 
Figure 6: Forest plot comparing rates for occurrence of fever and infection during medical 
abortion at home among women who performed self-assessment of outcome at home and 
routine clinic follow-up 
The point estimate (RR= 0.41; 95% CI = 0.08 to 2.12) for the pooled effect shows that there 
was 59% lower risk of occurrence of fever and infection during medical abortion at home in 
the self-assessment group compared to the clinic follow-up group. The p-value of test for 




the intervention and control group. However, there was moderate heterogeneity among the 
included studies in regard to occurrence of fever and infection (I2= 62%). Thus, the pooled 
effect from two included studies showed there is a lower risk in the self-assessment group for 
occurrence of fever and infection during medical abortion than in routine clinic follow-up 
group, but the difference is not statistically significant. 
In the study done by Ngoc et. al. 2014, the values for occurrence of fever and infection could 
not be used because the values were only given for patient who did interim visit (47).  
Only two of the included studies measured the rates for drug administration for haemorrhage 
during medical abortion at home. The meta-analyses result of this outcome is shown in figure 
7. 
 
Figure 7: Forest plot comparing rates for drug administration for haemorrhage during medical 
abortion at home among women who performed self-assessment of outcome at home and 
routine clinic follow-up 
The point estimate (RR= 1.81; 95% CI = 0.61 to 5.35) for the pooled effect shows that there 
was a higher risk of haemorrhage requiring drug administration during medical abortion at 




heterogeneity among the included studies in regard to drug administration for haemorrhage (I2= 
0%). The p-value of test for overall effect was 0.28, which means there was no statistically 
significant difference between the intervention and control group. Thus, the pooled effect from 
two included studies showed there is higher risk in the self-assessment group for need for drug 
administration for haemorrhage during medical abortion than in routine clinic follow-up group, 
however, the difference is not statistically significant. 
In the study done by Iyengar et. al. 2015, the event for drug administration for haemorrhage 
was zero in both the self-assessment and the clinic follow-up group. Because zero event is not 
estimable, 1 event was added in both the control and experimental group (14). 
Other outcomes related to safety of medical abortion at home versus clinic follow-up are shown 
in table 2. 
Table 2: Other outcomes related to safety of medical abortion at home versus clinic follow-up 
 
Study Outcome RR, Mantel-
Haenszel (M-H) 
Random (95% CI) 
Test for overall effect 
Iyengar  et.al., 
2015 (14) 
Need for blood 
transfusion 
0.31 (0.01, 7.53) Z= 0.72 (P=0.47) 




0.31 (0.01, 7.53) Z= 0.72 (P=0.47) 
Iyengar et.al., 
2015 (14) 
Pain 1.46 (0.72, 2.96) Z= 1.05 (P=0.29) 




1.05 (0.78, 1.43) Z= 0.33 (P=0.74) 
Oppegaard et.al., 
2015 (13) 
Clinic visit 1.25 (0.75, 2.09) Z= 0.85 (P=0.40) 
There were a few other outcomes of interest, but because they were only reported in one of the 




2015, the researchers reported outcomes such as need for blood transfusion due to haemorrhage, 
admission to hospital, and pain (defined as severe abdominal pain). In the study done by Ngoc 
et. al. 2014, the data for admission to hospital could not be used as the data were only given for 
patients who did interim visit (47). Additionally, in the study done by Oppegaard et. al. 2015, 
the researchers reported on the additional phone consultation and clinic visit. 
The RR was 0.31 (95% CI: 0.01 to 7.53) for both outcomes (need for blood transfusion and 
admission to hospital). It means there was 69% lower risk for need for blood transfusion in case 
of haemorrhage and admission to hospital in the self-assessment group compared to the clinic 
follow-up group. The CI was wide. This may be because the total population and the number 
of events was somewhat low. The p-value was 0.47, which means there was no statistically 
significant difference between the intervention and control group.  
The RR was 1.46 (95% CI = 0.72 to 2.96) for pain, meaning that there was a higher risk for 
severe abdominal pain in the self-assessment group compared to the clinic follow-up group. 
However, the p-value was 0.29, which means there was no statistically significant difference 
between the intervention and control group.  
The RR was 1.05 (95% CI = 0.78 to 1.43) for additional phone consultation. That is, there was 
a higher risk for additional phone consultation in the self-assessment group compared to the 
clinic follow-up group. The p-value was 0.74, which means there was no statistically significant 
difference between the intervention and control group.  
The RR was 1.25 (95% CI = 0.75 to 2.09) for clinic visit. This means that there was a higher 
risk for clinic visit beside scheduled visit in the self-assessment group compared to the clinic 
follow-up group, but the p-value was 0.40, which means there was no statistically significant 




In summary, the risk of complications such as need for surgery, fever and infection, and need 
for blood transfusion was lower in the self-assessment group compared to the routine clinic 
follow-up group. The risk of other complications, such as haemorrhage, drugs for haemorrhage, 
and pain was higher in the self-assessment group compared to the clinic follow-up group. 
However, the results were statistically non-significant for all these outcomes. Therefore, it can 
be concluded that self-assessment of the outcome of medical abortion at home is as safe as 
routine clinic visit.  
Secondary outcome: Acceptability of assessment of outcome of medical abortion at home 
versus clinic follow-up. All the four included studies measured acceptability of the follow-up 
technique in terms of preference in the event of future medical abortion. Preferences of follow-
























































349 286 81.95 274 82 29.93 
Oppegaard 
et.al., 2015 
458 400 87.34 466 333 71.46 
Ngoc et.al., 
2014 
686 606 88.34 642 256 39.88 
Platais 
et.al., 2015 
1199 913 76.15 1199 577 48.12 
Total 2692 2205 
 
81.91 % 2581 1248 
 
48.35% 
Test for overall effect Z=3.78 (p=0.0002) 





349 63 18.05 274 192 70.07 
Oppegaard 
et.al., 2015 
458 58 12.66 466 133 28.54 
Ngoc et.al., 
2014 
686 72 10.50 642 385 59.97 
Platais 
et.al., 2015 
1199 115 9.59 1199 349 29.11 
Total 2692 308 11.44% 2581 1059 41.03% 
Test for overall effect Z=6.73 (p<0.00001) 
No preferences Paul et.al., 
2015 
N/S N/S N/S N/S N/S N/S 
Oppegaard 
et.al., 2015 
N/S N/S N/S N/S N/S N/S 
Ngoc et.al., 
2014 
686 8 1.17 642 1 0.16 
Platais 
et.al., 2015 
1199 171 14.26 1199 273 22.77 
Total 1885 179 9.50% 1841 274 14.88% 




The above table shows the percentage of women in the self-assessment group and the clinic 
follow-up group across different studies preferring different follow-up techniques in the event 
of a future medical abortion. A higher percentage of women (81.91%) preferred phone follow-
up in the event of future medical abortion in the self-assessment group compared to the routine 
clinic follow-up group (48.35%). The p-value in the ‘test of overall effect’ was p=0.0002, which 
means there was a statistically significant difference between the intervention and control group 
regarding preference of phone follow-up if they performed future medical abortion. 
Additionally, a lower percentage of women (11.44%) preferred clinic follow-up in the event of 
future medical abortion in the self-assessment group compared to women in the routine clinic 
follow-up group (41.03%). The p-value in the ‘test of overall effect’ was p<0.00001, which 
means there was a statistically significant difference between the intervention and control 
groups regarding preference of clinic follow-up if they performed future medical abortion. 
Further, fewer women (9.50%) in the self-assessment group compared to the routine clinic 
follow-up group (14.88%) had no preference for a follow-up technique in the event of a future 
medical abortion, but the difference was not statistically significant (p=0.65). Hence, the 
acceptability of follow-up technique is significantly greater for self-assessment compared to 
routine clinic follow-up. 
Other outcome of interest: Loss to follow up is also measured in this systematic review. The 

































365 7 1.92 366 11 3.01 
Oppegaard 
et.al., 2015 
458 90 19.65 466 108 23.18 
Ngoc et.al., 
2014 
697 4 0.57 710 58 8.17 
Platais 
et.al., 2015 
1200 1 0.08 1200 0 0 
Total 2720 102 3.75 % 2742 177 6.46 % 
The above table shows the percentage of loss to follow-up in the self-assessment group and in 
the clinic follow-up group across the four studies. In all the studies, the percentage of loss to 
follow-up in the self-assessment group was lower compared to the clinic follow-up group. In 
all the included studies, an average of 6.46% women were lost to follow-up in the clinic follow-
up group, whereas, an average of only 3.75% women were lost to follow-up in self-assessment 
group.  
3.5 Summary of findings (SoF) 
To measure the certainty of evidence, a GRADE assessment was performed. The GRADE 







Table 5: SoF table for primary outcome  
Effectiveness of self-assessment of outcome compared to routine clinic follow-up for medical abortion at 
home 
Population: Women who had requested a medical abortion at home up to 9 weeks of gestational age 
Setting: Low to high-resource setting countries 
Intervention: Self-assessment of outcome  
Comparison: Routine clinic follow-up  
Outcomes Anticipated absolute 
effects* (95% CI)  
Relative 
effect 
























(4 RCTs)  
⨁⨁⨁⨁ 
HIGH  
We are very confident that 
the true effect lies close to 
that of the estimate of the 
effect 0 per 100  
0 per 100 
(0 to 0)  
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio  
 
The GRADE assessment for the primary outcome defined as effectiveness of self-assessment 
of outcome of medical abortion was ‘high quality’. It means that one can be very confident that 
the estimate of the effect (RR=1.00; 95% CI= 0.99 to 1.01) lies close to the true effect. The 
absolute effect illustrates that fewer than zero per 100 women who perform medical abortion at 
home are unlikely to assess complete termination of pregnancy effectively compared to the 
routine clinic follow-up group. Thus, further research is very unlikely to change our confidence 
in the estimate of effect. The GRADE evidence table is found in Appendix 5. 




Table 6: SoF table for secondary outcomes 
 
Safety of self-assessment of outcome compared to routine clinic follow-up for medical abortion at home 
Population: Women who had requested a medical abortion at home up to 9 weeks of gestational age 
Setting: Low to high-resource setting countries 
Intervention: Self-assessment of outcome 
Comparison: Routine clinic follow-up  
Outcomes Anticipated absolute 
effects* (95% CI)  
Relative 
effect 






















4 per 100 





(4 RCTs)  
⨁⨁⨁◯ 
MODERATE a 
We are moderately confident in the 
effect estimate: The true effect is 
likely to be close to the estimate of the 
effect, but there is a possibility that it 
is substantially different 
Excessive 
bleeding  1 per 
100  
2 per 100 





(4 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Our confidence in the effect estimate 
is limited: The true effect may be 
substantially different from the 
estimate of the effect 
Fever and 
Infection  4 per 
100  
2 per 100 





(2 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Our confidence in the effect estimate 
is limited: The true effect may be 
substantially different from the 






1 per 100 





(2 RCTs)  
⨁⨁⨁◯ 
MODERATE c 
We are moderately confident in the 
effect estimate: The true effect is 
likely to be close to the estimate of the 
effect, but there is a possibility that it 
is substantially different 
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio  
Explanations 
a. Somewhat wide CI, the total sample size and the number of events are low.  
b. Heterogeneity is moderate  




The GRADE assessments for secondary outcomes defined as need for surgery, occurrence of 
haemorrhage (excessive bleeding), occurrence of fever and infection, and need for drugs 
administration for haemorrhage show that the certainty in the estimates ranges from moderate 
to low.  
For the outcome need of surgery, one can be moderately confident in the estimate of the effect. 
Although the true effect is likely to be close to the effect estimate (RR=0.92; 95% CI= 0.70 to 
1.21), there is a possibility that it is substantially different. The absolute effect illustrates that 
four per 100 women who perform medical abortion at home have need for surgery compared 
to the women in routine clinic follow-up. Thus, further research is likely to have an important 
impact on our confidence in the estimate and may change the estimate. 
For the outcome haemorrhage (excessive bleeding), there is limited confidence in the estimate 
of the effect. The true effect may be substantially different from the effect estimate (RR=1.48; 
95% CI= 0.84 to 2.60). The absolute effect illustrates that two per 100 women who perform 
medical abortion at home have haemorrhage compared to the women in routine clinic follow-
up. Thus, further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate. 
For the outcome fever and infection, there is limited confidence in the estimate of the effect. 
The true effect may be substantially different from the effect estimate (RR=0.41; 95% CI= 0.08 
to 2.12). The absolute effect illustrates that two per 100 women who perform medical abortion 
at home have fever and infection compared to the women in routine clinic follow-up. Thus, 
further research is very likely to have an important impact on our confidence in the estimate of 




For the outcome drug for haemorrhage, one can be moderately confident in the estimate of the 
effect. Although the true effect is likely to be close to the effect estimate (RR=1.81; 95% CI= 
0.61 to 5.35), there might be a possibility that it is substantially different. The absolute effect 
illustrates that one women per 100 women who perform medical abortion at home have need 
for drugs during haemorrhage compared to the women in routine clinic follow-up. Thus, further 
research is likely to have an important impact on our confidence in the estimate of effect and 























CHAPTER 4: DISCUSSION 
 
4.1 Summary of main results  
This systematic review identified four randomized controlled studies that met all the pre-
specified inclusion criteria. Evidence from these well-conduced RCTs showed there is no 
difference in complete abortion rates between self-assessment of outcome of medical abortion 
at home and routine clinic follow-up. It also showed that there are no serious complications 
related to self-assessment at home and that self-assessment is as safe as routine clinic follow-
up. In addition, the results showed that women who performed self-assessment are likely to 
prefer the same follow-up method in the event of future medical abortion.  
4.2 Agreement with other reviews 
To the best of our knowledge, this review is the first to systematically evaluate effectiveness, 
safety, and acceptability of self-assessment of the outcome of medical abortion at home 
compared to routine clinic follow-up. Prior to this review, one review had compared 
effectiveness, safety, and acceptability of home-based to clinic-based medical abortion (15). 
Another review had provided evidence on alternative techniques to routine in-person follow-
up visits after medical abortion (41).  
Grossman et.al. 2010 concluded that alternatives to routine in-person follow-up visits after 
medical abortion – such as women’s self-assessment, clinical assessment, serum hCG 
measurement, and UPTs – are accurate at diagnosing ongoing pregnancy. Further, UPT 
combined with self-assessment or clinicians’ assessment is considered one of the promising 
follow-up modalities with relatively high sensitivities. However, these UPTs were not designed 




UPTs (41). In this review, the self-assessment of outcome was performed by UPTs (LSUPT 
and SQUPT), which were easy to use, commercially available, and had high sensitivities and 
specificities (13, 14, 47-49). Ngo et.al. 2011 concluded that there was no difference in 
effectiveness or acceptability between medical abortion performed at home and clinic across 
countries (15). Similarly, in this systematic review, the meta-analyses showed that assessment 
of the complete termination of pregnancy of medical abortion is equally effective whether it is 
done at home by women themselves or in a routine clinic follow-up by clinicians.  
Regarding safety analysis, Ngo et.al. 2011 concluded that complications arising in women who 
performed medical abortion at home are rare, therefore, it can be considered a safe method (15). 
The findings from the current review are similar. Some of the complications, such as need for 
surgery, fever and infection, need for blood transfusion, were associated with lower risks, and 
while other complications, such as haemorrhage (excessive bleeding), drugs for haemorrhage, 
and pain were associated with higher risk in the self-assessment group compared to the clinic 
follow-up group. However, because there were no statistically significant differences between 
the groups regarding any of these outcomes, it can be concluded that self-assessment of the 
outcome of medical abortion at home is as safe as routine clinic follow-up.  
Ngo et.al. 2011 also concluded that women who performed home-based medical abortion 
appeared satisfied and likely to choose the method again. The current review also sheds some 
light on the issue of acceptability of medical abortion. It showed that self-assessment by women 
combined with phone follow-up technique was preferred by more women in the self-assessment 
group and considerably more women in the clinic follow-up group in the event of future medical 
abortion. Hence, more women were likely to choose this technique again in the future. 
However, the reasons behind the preference were not assessed. Acceptability is likely to be 




reasons for acceptability might be ease of use, effectiveness of the technique, and lower cost. 
Besides, the studies included in the current systematic review had not measured the tolerance 
rate for pain or bleeding; this might change the preference of women in the event of future 
medical abortion. 
Further, in all the included studies, fewer women were lost to follow-up in the self-assessment 
group compared to the clinic follow-up group, which was similar in the study conducted by 
Ngo et.al. 2011. This might be because of the ease to follow-up by a telephone call. 
It must be mentioned that there are a few studies listed in clinicaltrials.gov. Among these 
studies, three studies were completed but their results were not yet published, two studies are 
in progress, and one study has not yet started. Therefore, these studies could not be screened 
for inclusion. It is possible, but unlikely, that the inclusion of these studies would change the 
main result of this review. 
Furthermore, it was identified that there were only two research groups — Karolinska Institutet, 
Stockholm (13, 14) and Gynuity Health Projects, New York (47, 49) — that performed all the 
four included studies. This may raise the risk of bias, if the researchers were directly benefiting, 
in particular financially, from the finding of specific results. It is believed that this is unlikely, 
because funders had no role in the conduct of the study (design, collection, analysis, 
interpretation of data, writing of report) and no medical industries were involved in these 
studies. However, different study groups are encouraged to contribute to the knowledge base 




4.3 Certainty of the evidence 
The RoB assessment showed that none of the included studies had high RoB, but there were 
some forms of plausible bias in each of the studies because none of them had low RoB for all 
the domains assessed.  
In order to provide a judgement about the certainty of the evidence (quality of evidence), a 
GRADE assessment was conducted. One of the major factors that must be considered when 
providing a judgement about the quality of evidence is study design. In general, RCTs provide 
stronger evidence than observational studies. Henceforth, if the randomized trials are without 
important limitations, they are considered to provide high quality evidence (45). All of the four 
included studies in this review were RCTs. However, there are other factors for which the 
quality of evidence for each outcome can be rated down. Here, evidence was downgraded for 
a few secondary outcomes. In the current systematic review, publication bias could not be 
statistically assessed because the number of included studies was less than ten (45). However, 
it is unlikely that studies have been missed because there was a thorough search in different 
databases.  
It was judged that the quality of evidence for the primary outcome was high quality. This was 
because there was no serious issues regarding RoB, inconsistency of results, indirectness of 
evidence, and imprecision. Thus, further research is very unlikely to change our confidence in 
the estimate of effect about effectiveness of self-assessment. This gives firm ability to make 
conclusion about effectiveness of the technique.  
However, the quality of evidence for the secondary outcomes showed that the quality ranged 
from moderate to low quality. The outcomes need for surgery and need for drug administration 




concerning imprecision. This was because the total sample size and the number of events were 
low. Thus, further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. Likewise, the outcomes, occurrence of 
haemorrhage (excessive bleeding) and occurrence of fever and infection, were rated as low 
quality evidence because they had some limitations with respect to imprecision and 
inconsistency. This was because the total sample size and the number of events were low and 
there was moderate heterogeneity in the events among the various included studies. Hence, 
further research is very likely to have an important impact on our confidence in the estimate of 
effect and is likely to change the estimate.  
4.4 Transferability 
The findings from this review are generalizable to different resource (income and education) 
setting countries because the included studies were carried out from low to high resource 
settings countries. However, the findings from this review only apply to medical abortion with 
mifepristone, which is taken orally at clinic, combined with misoprostol, administered with 
different routes at home 24-48 hours later. In addition, the findings only apply to self-
assessment done by using UPTs by women themselves. Hence, the findings cannot be 
generalized to settings where different regimens for medical abortion are used or different self-
assessment techniques are used. 
4.5 Ethics 
The ethical aspects of abortion, whether it is surgical or medical abortion, are highly 
controversial and debated. The controversy of abortion surrounds the moral, religious, and legal 
status of induced abortion (50). In ancient times, abortion was mainly considered in the context 
of family planning, selection of gender, population control, or the patriarch’s property rights 




in terms of the prospective child’s right (52). However, these days, the debate is mainly focused 
on the rights of the prospective mother and child. Many people believe in the ‘pro-choice’ 
movement, which focuses on the rights of women to take a decision on whether or not to 
terminate a pregnancy. Still many other people believe in the ‘pro-life’ movement, which 
focuses on the right of the embryo or fetus to gestate to term and be born (53). In addition, 
different religions have varying views on the moral implications of abortion (54). Further, a 
country’s legislative power to make abortion laws plays the most significant role. Abortion is 
now legal in almost all of the countries in the world; however, there are still a few exceptional 
cases. Six countries do not allow abortion under any circumstances, while a few other nations 
have very strict laws and tight controls, such that to have an abortion legally is almost close to 
impossible. Keeping these into consideration, when it is broadly viewed, abortion laws are 
towards liberalism, however it is still a major ethical concern (55).  
If rights of women are not taken into considerations and if women are not allowed to make 
decisions of their choice about their own body, the incidence of unsafe abortion increases due 
to illegalization of abortion, which will then increase maternal mortality. A global study 
conducted by the WHO and the Guttmacher Institute, stated that most unsafe abortions occur 
where abortion is not legalized (56). Legalization of abortion is able to prevent the unnecessary 
suffering and deaths of women and protect their lives (57). Thus, one can argue that although 
the fetus has a right to life, abortion is morally permissible because women should have the 
right to control and make decisions for their own body and their life-support functions (58), 
The present world’s  maternal health community has also shifted its thinking by viewing women 
as highly valuable contributors to society. Women are now recognized as more than mothers. 




and societies. Women’s lives can and must be saved and women’s rights are worth fighting for, 
highlight authors of a Lancet article (59).  
The medications or the assessment techniques used for performing abortions also should not 
affect the women negatively and they should be ethically acceptable. Studies have shown that 
the medications used in medical abortion are safe and effective. There are no reports of any 
long-term risks or major side-effects (60). Further, the assessment and follow-up techniques, 
whether it is routine clinic follow-up or self-assessment at home, is unlikely to have any major 
harm to the health of women (61). Therefore, it can be said that there are no ethical issues 
regarding the medications or the assessment technique used. 
Moreover, all the included studies in this systematic review were approved by ethical 
committee boards of the respective countries. All eligible women consented to participate and 
gave written informed consent before participating in the trials. The publications clearly stated 
that there was no role of funders in the study design, collection, analysis or interpretation of 
data and writing of the report. In addition, it was mentioned that there was no interest of any 
medical industries in these studies.  
4.6 Strengths and weaknesses  
This systematic review is conducted in accordance with the criteria in the Cochrane Handbook 
for Systematic Reviews of Interventions, which has increased its validity. Two reviewers were 
involved at its various steps of this review to reduce the risk of bias. The search strategy was 
tested, revised, and then finalized by search librarians. The searches were carefully executed in 
a range of different databases. Publication bias could not be statistically assessed because of 
the low number of studies that was included. However, it is unlikely that studies have been 




is that studies conducted in different languages could not be included due to lack of resources 
to translate different languages. However, no studies in languages other than English, which 
seemed eligible for inclusion, were identified. 
Whenever possible, meta-analyses were conducted. This is a major strength of this systematic 
review. However, not all of the four included studies reported the same secondary outcomes, 
particularly with regard to safety. Thus, the number of events for secondary outcomes was 
somewhat low. The tool for assessing the main outcome was different across studies: Iyengar 
et.al. 2015 used LSUPT (14), while the others used SQUPT (13, 47, 49). Likewise, the 
measurement techniques at clinics varied from study to study: Iyengar et.al. 2015 used LSUPT 
(14), Oppegaard et.al. 2015 used low sensitivity urine hCG test, measurement of hCG serum, 
or ultrasonography (13), Ngoc et.al. 2014 used bimanual examination and transvaginal 
ultrasonography (47), while Platais et.al. 2015 used clinical examination, women’s report of 
symptoms and ultrasound (49). Because of these variations, random effect models were used. 
The variation in assessments and associated choice of analysis might explain some of the 
heterogeneity and wider confidence interval. Heterogeneity can be assessed by sensitivity 
analyses or sub-group analyses. However, neither of these techniques were possible in the 
current systematic review because of the lower number of studies included.  Despite these 
limitations, the systematic review is able to draw some conclusions about the safety of medical 
abortion at home. 
Sub-group analyses in regard to education and income could not be performed. Only one study 
was done in a low-resource settings country where the literacy rate among study participants 
was 45% only; the other three studies were carried out in high-resource setting countries, where 




4.7 Implications of research findings 
The findings of this systematic review may have implications for practice/policy and further 
researches, which are presented below: 
4.7.1 Implication for practice/policy 
This systematic review offers encouraging evidence about the value of self-assessment of the 
outcome of medical abortion at home combined with telephone follow-up or home visit. Thus, 
the findings of this review have several potential implications for practice and policy. 
In poor-resource settings or in sparsely populated areas, where access to health facilities are 
limited, ultrasound examination is limited, or abortion services are socially undesirable or not 
acceptable, the self-assessment of the outcome of medical abortion with UPTs and a simple 
follow-up technique like telephone call or home visit gives a viable option. This is because 
UPTs are not only easy to use and also easily available in such resource settings, but also 
effective and safe. Additionally, this method is equally relevant in high resource settings. It 
helps to shorten the waiting times for patients and reduce the need for medical resources in high 
resource settings. It also saves time and energy for women who travel long distances to clinics, 
who have to arrange childcare, or take time off from household or work duties. Moreover, this 
technique provides women with a confidential and friendly environment to confirm abortion 
success at home. This method can encourage women to access abortion at an early gestational 
age, which helps to reduce risks and complications related to abortion at later gestational ages. 
Further, this method can reduce the clinic visits giving the health care providers more time for 




4.7.2 Implication for further research 
Implications for further research is recommended using the EPICOT (Evidence, Population, 
Intervention, Comparison, Outcome, Time-frame) format. 
Even though high quality evidence is drawn from this review, researchers are encouraged to 
conduct further research on different aspects of this topic in various study areas. This will 
provide a broader and more diverse picture of the current abortion issue, in addition to 
strengthen the evidence. Studies should also be conducted to investigate the effectiveness of 
self-assessment of outcome of medical abortion at home and its safety in vulnerable groups, 
such as HIV-positive women. Further research is needed on medical abortion carried out by 
different regimens and doses other than mifepristone and misoprostol. In addition, studies 
should be conducted with various kinds of self-assessment techniques combined with simpler 
follow-up techniques, other than UPT kits with telephone follow-up. Studies should be 
conducted to measure long-term outcomes such as fertility, to know whether it is better or worse 
in those who had self-assessment compared to clinical assessment. Moreover, studies should 
also analyse the reasons for preferences of follow-up technique. Further, the preference of the 
technique by the patients’ partner or family members should be analysed, as this would give a 
broader and stronger evidence base about the attitude and acceptability of community towards 
this technique. The search for this review is dated until the mid of February 2017. Further 
reviews should include today’s ongoing studies. Furthermore, researchers should include 
studies published in other languages besides English.  
There is a rapid rise in health care costs in the present world. Therefore, it is essential that health 
care policy makers focus on developing interventions that are not only effective but also cost-
effective and affordable. Self-assessment of medical abortion can be one of the intervention 




the included studies, it is impossible to draw any conclusions on the cost-effectiveness of self-
assessment. Thus, there is a clear need for further research on economic evaluation to determine 
cost-effectiveness of self-assessment.  
4.8 Author’s conclusion 
This systematic review summarizes and presents that there is high quality evidence that the 
effectiveness of self-assessment of the outcome of medical abortion at home is not inferior to 
routine clinic follow-up. Although there was moderate to low quality evidence for the safety of 
this assessment technique, there were no statistically significant differences between the 
groups. Thus, self-assessment at home appears to be as safe as routine clinic follow-up. 
Furthermore, the systematic review also sheds some light on the acceptability of follow-up 
method. It shows that the preference of follow-up technique is significantly greater for self-
assessment compared to routine clinic follow-up. 
Self-assessment of the outcome of medical abortion at home is a simple follow-up technique 
that has implications for policy makers and key stakeholders. Because it is comparable in 
effectiveness and safety to routine clinic follow-up, and feasible to implement, it can be 
incorporated as an alternative to abortion services in both low and high resource settings, giving 
women a choice whether to do the assessment by themselves or in clinics. This does not prevent 
women from choosing routine clinic follow-up. Rather, it gives women greater choice in 
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Appendix 1: Search strategy in electronic databases 
1.1 Medline (Date: 30th January, 2017) 
Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present  
Search Strategy: 
# Searches Results 
1 exp Abortion, Induced/ 41176 
2 "abort*".ab,kf,ti. 77889 
3 (fertilit* adj3 control* adj3 postconcept*).ab,kf,ti. 5597 
4 (term* adj3 preg*).ab,kf,ti. 24419 
5 1 or 2 or 3 or 4 109443 
6 exp Pregnancy Tests/ 4186 
7 (preg* adj3 test*).ab,kf,ti. 9002 
8 6 or 7 10819 
9 exp Diagnostic Self Evaluation/ 2114 
10 exp "Outcome Assessment (Health Care)"/ 960894 
11 exp Self Administration/ 12370 
12 exp Self Care/ 53961 
13 "home*".ab,kf,ti. 444771 
14 
(self* adj3 (assess* or administrat* or evaluat* or apprais* or use* or car* or 
perform*)).ab,kf,ti. 
87244 
15 or/9-14 1493334 
16 5 and 8 and 15 86 










1.2 Embase (Date: 30th January, 2017) 
Database(s): Embase Classic+Embase 1947 to 2017 January 26  
Search Strategy: 
# Searches Results 
1 exp induced abortion/ 35295 
2 "abort*".ab,kw,ti. 91552 
3 (fertilit* adj3 control* adj3 postconcept*).ab,kw,ti. 6 
4 (term* adj3 preg*).ab,kw,ti. 32092 
5 or/1-4 129016 
6 exp pregnancy test/ 5749 
7 (preg* adj3 test*).ab,kw,ti. 11004 
8 or/6-7 13507 
9 exp self evaluation/ 28395 
10 exp outcome assessment/ 376263 
11 exp drug self administration/ 11655 
12 exp self care/ 68201 
13 "home*".ab,kw,ti. 517492 
14 
(self* adj3 (assess* or administrat* or evaluat* or apprais* or use* or car* or 
perform*)).ab,kw,ti. 
103581 
15 or/9-14 1033234 
16 5 and 8 and 15 112 














1.3 CENTRAL (Date: 30th January, 2017) 
Search Name: Cochrane _New search 30th Jan 
Last Saved: 30/01/2017 12:14:27.581 
Description: 30th Jan, 2017 
ID Search  
#1 MeSH descriptor: [Abortion, Induced] explode all trees 
#2 abort*  (Word variations have been searched) 
#3 fertilit* near/3 control* near/3 postconcept*  (Word variations have been searched) 
#4 term* near/3 preg*  (Word variations have been searched) 
#5 #1 or #2 or #3 or #4  
#6 MeSH descriptor: [Pregnancy Tests] explode all trees 
#7 preg* near/3 test*  (Word variations have been searched) 
#8 #6 or #7  
#9 MeSH descriptor: [Diagnostic Self Evaluation] explode all trees 
#10 MeSH descriptor: [Outcome Assessment (Health Care)] explode all trees 
#11 MeSH descriptor: [Self Administration] explode all trees 
#12 MeSH descriptor: [Self Care] explode all trees 
#13 home*  (Word variations have been searched) 
#14 self* near/3 (assess* or administrat* or evaluat* or apprais* or use* or car* or 
perform*)  (Word variations have been searched) 
#15 #9 or #10 or #11 or #12 or #13 or #14  
#16 #5 and #8 and #15 Publication Year from 1991 to 2017 
Total Hits: 123 
Cochrane Review: 88 
Other Review: 3 














42 #11 AND #6 AND #5 




716,443 #10 OR #9 OR #8 OR #7 




53,263 TS=(outcom* near/3 assess*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 9 47 TS=(diagnost* near/3 self* near/3 evaluat*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 8 542,778 TS=home* 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 7 130,258 TS=(self* near/3 (assess* or administrat* or evaluat* or apprais* or use* or 
car* or perform*)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 6 7,009 TS=(preg* near/3 test*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 5 80,590 #4 OR #3 OR #2 OR #1 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 4 17,549 TS=(term* near/3 preg*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 3 0 TS=(fertilit* near/3 control* near/3 postconcept*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 2 4,991 TS=(induc* near/3 abort*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 1 66,268 TS=(abort*) 






1.5 CINAHL (Date: 1st February 2017) 
Search 
ID# Search Terms Search Options Actions 
S15 S5 AND S8 AND S14  Limiters - Published Date: 
19910101-20171231; English 
Language; Exclude MEDLINE 
records 
Search modes - Boolean/Phrase 
View 
Results (260) 
S14 S9 OR S10 OR S11 OR 
S12 OR S13  
Search modes - Boolean/Phrase View 
Results (536,900) 
S13 TX self* N3 (assess* or 
administrat* or evaluat* 
or apprais* or use* or 
car* or perform*)  
Search modes - Boolean/Phrase View 
Results (134,730)  
 
S12 TX home*  Search modes - Boolean/Phrase View 
Results (423,073) 
S11 (MH "Outcome 
Assessment")  
Search modes - Boolean/Phrase View 
Results (28,392) 
S10 (MH "Self Care+")  Search modes - Boolean/Phrase View 
Results (35,399) 
S9 (MH "Self 
Administration+")  
Search modes - Boolean/Phrase View 
Results (4,589)  
S8 S6 OR S7  Search modes - Boolean/Phrase View 
Results (5,919) 
S7 TX preg* N3 test*  Search modes - Boolean/Phrase View 
Results (5,917) 
S6 (MH "Pregnancy 
Tests+")  





S5 S1 OR S2 OR S3 OR 
S4  
Search modes - Boolean/Phrase View 
Results (30,280) 
S4 TX term* N3 preg*  Search modes - Boolean/Phrase View 
Results (8,257) 
S3 TX fertilit* N3 control* 
N3 postconcept*  
Search modes - Boolean/Phrase View Results (1) 
S2 TX abort*  Search modes - Boolean/Phrase View 
Results (25,338) 
S1 (MH "Abortion, 
Induced+")  
Search modes - Boolean/Phrase View 
Results (7,457) 
 
1.6 ClinicalTrials.gov (Date: 1st February, 2017) 
Search Terms: abortion AND “pregnancy test” 
No. of hits=29 
 
1.7 SCOPUS (Date: 8th February, 2017) 
History 
Count 
Search Terms Results 
18 ( ( TITLE-ABS-KEY ( abort* ) )  OR  ( TITLE-ABS-
KEY ( fertilit*  W/3  control*  W/3  postconcept* ) )  OR  ( TITLE-
ABS-KEY ( term*  W/3  preg* ) ) )  AND  ( TITLE-ABS-
KEY ( preg*  W/3  test* ) )  AND  ( ( TITLE-ABS-
KEY ( outcome*  W/3  assess* ) )  OR  ( ( TITLE-ABS-
KEY ( self*  W/3  assess* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  administrat* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  evaluat* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  apprais* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  perform* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  use* ) )  OR  ( TITLE-ABS-





17 ( TITLE-ABS-KEY ( outcome*  W/3  assess* ) )  OR  ( ( TITLE-
ABS-KEY ( self*  W/3  assess* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  administrat* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  evaluat* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  apprais* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  perform* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  use* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  car* ) )  OR  ( TITLE-ABS-KEY ( home* ) ) ) 
1,413,325 
16 ( TITLE-ABS-KEY ( self*  W/3  assess* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  administrat* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  evaluat* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  apprais* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  perform* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  use* ) )  OR  ( TITLE-ABS-
KEY ( self*  W/3  car* ) )  OR  ( TITLE-ABS-KEY ( home* ) )  
1,024,569 
15 ( TITLE-ABS-KEY ( abort* ) )  OR  ( TITLE-ABS-
KEY ( fertilit*  W/3  control*  W/3  postconcept* ) )  OR  ( TITLE-
ABS-KEY ( term*  W/3  preg* ) )  
164,848 
14 TITLE-ABS-KEY ( outcome*  W/3  assess* )  412,469 
13 TITLE-ABS-KEY ( home* )  809,548 
12 TITLE-ABS-KEY ( self*  W/3  car* )  68,897 
11 TITLE-ABS-KEY ( self*  W/3  use* )  53,356 
10 TITLE-ABS-KEY ( self*  W/3  perform* )  21,578 
9 TITLE-ABS-KEY ( self*  W/3  apprais* )  1,963 
8 TITLE-ABS-KEY ( self*  W/3  evaluat* )  42,648 
7 TITLE-ABS-KEY ( self*  W/3  administrat* ) 18,166 
6 TITLE-ABS-KEY ( self*  W/3  assess* )  52,941 
5 TITLE-ABS-KEY ( preg*  W/3  test* )  15,099 
4 TITLE-ABS-KEY ( #1  OR  #2  OR  #3 )  18,301,284 
3 TITLE-ABS-KEY ( term*  W/3  preg* )  33,665 
2 TITLE-ABS-KEY ( fertilit*  W/3  control*  W/3  postconcept* ) 5,159 





1.8 British Nursing Index (Date: 8th February, 2017) 
Search Strategy from ProQuest 
08 February 2017 11:41 
Set# Searched for Databases Results 
S1 SU.EXACT.EXPLODE("Abortion") British Nursing Index 459° 
S2 abort* British Nursing Index 864° 
S3 fertilit* NEAR/3 control* NEAR/3 
postconcept* 
British Nursing Index 0° 
S4 term* NEAR/3 preg* British Nursing Index 107° 
S5 SU.EXACT.EXPLODE("Abortion") OR 
abort* OR (fertilit* NEAR/3 control* 
British Nursing Index 957° 
S6 preg* NEAR/3 test* British Nursing Index 155° 
S7 home* British Nursing Index 16837° 
S8 outcome* NEAR/3 assess* British Nursing Index 820° 
S9 SU.EXACT.EXPLODE("Self Care") British Nursing Index 4117° 
S10 self* NEAR/3 assess* British Nursing Index 1103° 
S14 self* NEAR/3 administrat* British Nursing Index 101° 
S15 self* NEAR/3 evaluat* British Nursing Index 412° 
S16 self* NEAR/3 apprais* British Nursing Index 44° 
S17 self* NEAR/3 use* British Nursing Index 909° 
S18 self* NEAR/3 car* British Nursing Index 5409° 
S19 self* NEAR/3 perform* British Nursing Index 236° 
S20 home* OR (outcome* NEAR/3 assess*) 
OR SU.EXACT.EXPLODE("Self Care") 




S21 (self* NEAR/3 administrat*) OR (self* 
NEAR/3 evaluat*) OR (self* NEAR/3 
British Nursing Index 553° 
S22 (self* NEAR/3 use*) OR (self* NEAR/3 
car*) OR (self* NEAR/3 perform*) 
British Nursing Index 6193° 
S23 (home* OR (outcome* NEAR/3 assess*) 
OR SU.EXACT.EXPLODE("Self Care") 
British Nursing Index 22369° 
S24 (SU.EXACT.EXPLODE("Abortion") 
OR abort* OR (fertilit* NEAR/3 
British Nursing Index 1° 
S25 (SU.EXACT.EXPLODE("Abortion") 
OR abort* OR (fertilit* NEAR/3 
British Nursing Index 1° 
 
1.9 WHO (ICTRP) (Date: 7th February, 2017) 
Search Terms: abortion “pregnancy test” 
Word Search: Anywhere in the article 
Total Hits: 47 
1.10 Google Scholar (Date: 10th February 2017) 
Search terms: abortion "pregnancy test" home 
Year: 1991 to 2017 
Words Search: Anywhere in the article 
Total Hits: 8,380 



































Records identified through database 
searching  
(n = 1031) 
Additional records identified 
through other sources  
(n = 38) 
Records screened with titles and abstract  
(After removing duplicates) 
(n =877) 
Records excluded  
(n = 755) 
Records eligible for full 

















Full-text articles excluded, 
with reasons  







Studies included in 
qualitative synthesis  
(studies=4, publication=5) 
Studies included in 
quantitative synthesis 
(meta-analysis) 




Appendix 3: Excluded studies read in full text 
 
3.1 Studies and publications from different databases 
Author Year Title Reasons for 
exclusion 
Beckman, 
Linda J (62) 
1997 Experience and acceptability of medical abortion with 
mifepristone and misoprostol among US women 
Not relevant 
intervention and 




2001 Single women's experiences of premarital pregnancy and 
induced abortion in Lombok, Eastern Indonesia 
Not relevant data 
Bjørge, Line 
(64) 
2001 Early pregnancy termination with mifepristone and 
misoprostol in Norway 
Not relevant 
intervention 
Blum, J.  
(65) 
2012 Using a semi-quantitative pregnancy test to determine the 





2012 Can at-home semi-quantitative pregnancy tests serve as a 






2016 Randomized trial assessing home use of two pregnancy 
tests for determining early medical abortion outcomes at 3, 
7 and 14days after mifepristone 
Not relevant data 
Blumenthal, 
P. (68) 
2009 Preliminary results of the semi-quantitative pregnancy test 





2001 Early Medical Abortion with Methotrexate and 
Misoprostol: Outcomes and Satisfaction Among Women 






2014 RU OK? The acceptability and feasibility of remote 




Hillary (71)  
2010 Home administration of misoprostol for early medical 






2014 The long gestation of the modern home pregnancy test Historical article 
Bygdeman, 
M. (73) 






2012 Self-assessment of success of early medical termination of 





2012 Telephone follow-up and self-performed urine pregnancy 








2015 Can women determine the success of early medical 
termination of pregnancy themselves? 
Not relevant 
study design 
Chen, M. J. 
(76) 




Janet E (77) 
2013 Health consumption as work: The home pregnancy test as a 
domesticated health tool 
Not relevant data 
Christopher, 
E. (78) 
1992 Welcome visitors Not relevant 










2007 Medication abortion employing routine sequential 








2007 Can mifepristone medical abortion be simplified?: A 
review of the evidence and questions for future research 
Not relevant data 
Coelho, H. 
L. (82) 
1994 Misoprostol: The experience of women in Fortaleza, Brazil Not relevant data 
Collins, D. 
(83) 
2011 Alleged misdiagnosis of missed abortion Not relevant 




2015 Self-assessment of medical abortion using a low-sensitivity 
pregnancy test, checklist and text messages in the South 





2016 Instruction-only versus demonstration of a low sensitivity 
pregnancy test for self-assessment of medical abortion in 






2015 Assessment of completion of early medical abortion using 
a text questionnaire on mobile phones compared to a self-
administered paper questionnaire among women attending 








2014 Mobile phone messages to provide support to women 
during the home phase of medical abortion in South Africa: 







1995 A randomized trial comparing misoprostol three and seven 











1996 Methotrexate and misoprostol for early abortion: a 





2014 Simplifying medical abortion provision: The role of at-





2016 Self-administered multi-level pregnancy tests in simplified 





2007 Is misoprostol a safe, effective and acceptable alternative to 
manual vacuum aspiration for postabortion care? Results 
from a randomised trial in Burkina Faso, West Africa 
Not relevant data 
Dunn, 
Sheila (93)   














2003 Verifying the effectiveness of medical abortion; ultrasound 














2002 Having an abortion using mifepristone and home 












2007 Clinical utility of urine pregnancy assays to determine 





2012 Early medical abortion using low-dose mifepristone 




study design  
Gomperts, 
R. (101) 





2008 Using telemedicine for termination of pregnancy with 
mifepristone and misoprostol in settings where there is no 
















2011 Alternatives to ultrasound for follow-up after medication 







2007 Accuracy of a semi-quantitative urine pregnancy test 
compared to serum beta-hCG measurement: a possible 














2011 Effectiveness and acceptability of medical abortion 





2007 Randomised controlled trial comparing the efficacy of 
same-day administration of mifepristone and misoprostol 







2002 Could American women use mifepristone-misoprostol pills 





2016 Feasibility of self-performed urine pregnancy testing for 











2012 Outcomes of very early medical termination of pregnancy 




Helena (112)  
2003 WHO multinational study of three misoprostol regimens 
after mifepristone for early medical abortion. I: Efficacy 
Not relevant data 
Hickey, M. 
(16) 
2015 Follow-up after medical abortion: Does simple equal safe? Commentary 
Hingorani, 
V. (113) 
1989 AN ANTIPROGESTIN STEROID AND PGE2 FOR AN 





1995 Mifepristone and vaginal misoprostol are effective, 






1992 Women's evaluation of three early abortion methods Not relevant data 
Isley, M. M. 
(116) 






2012 Can women accurately assess the outcome of medical 




Bliss (118)  
2011 Expanding medical abortion: can medical abortion be 












2007 Medical methods for first trimester abortion (Review) Not relevant 




2011 Medical methods for first trimester abortion Not relevant data 
Kunwar, S. 
(121) 










2007 Can mifepristone medication abortion be successfully 






2013 The role of a semi-quantitative urine pregnancy test after 
uterine evacuation for very early, undesired pregnancy: A 
pilot randomized controlled trial 
Conference 
paper 
Lohr, P. A. 
(125) 















2013 Simplified medical abortion using a semi-quantitative 





2010 Preliminary results of the role of semiquantitative 












2013 Women's satisfaction with early home medical abortion 






K. R. (132) 
2003 Prostaglandins for first-trimester termination Not relevant data 
Michie, L. 
(133) 
2014 Simplified follow-up after early medical abortion: 12-
month experience of a telephone call and self-performed 





2005 Randomized trial of mifepristone and buccal or vaginal 







2006 The role of urine pregnancy testing in facilitating access to 








2007 Increasing access to safe abortion services in rural India: 






2011 Comparative effectiveness, safety and acceptability of 






Ngoc, N. T. 
N. (137) 
2012 Alternative follow-up with a semi-quantitative pregnancy 





Nhu (138)  
2004 Is home‐based administration of prostaglandin safe and 
feasible for medical abortion? Results from a multisite 






2010 Teenage pregnancy and abortion Not relevant 
data; No full text 
available 
Okonofua, 
Friday (140)  
2014 Acceptability and feasibility of medical abortion with 






2015 Nurse versus physician-provision of early medical abortion 





Hae (142)  




study design  
Paul, M 
(143) 
2014 The feasibility of simplified follow-up after medical 






checklist in Rajasthan, India: A study protocol for a 
randomized control trial 
Paul, M 
(144) 
2014 Simplified follow-up after medical abortion using a low-
sensitivity urinary pregnancy test and a pictorial instruction 
sheet in Rajasthan, India - study protocol and intervention 




2013 Feasibility and acceptability of using the DUO-test after 
medical abortion in rural India- Findings from a pilot study 





1999 Office management of early induced abortion Not relevant data 
Perriera, L. 
K. (147) 




2015 The role of auxiliary nurse-midwives and community 
health volunteers in expanding access to medical abortion 





Helen C (34) 
2001 Mifepristone followed on the same day by vaginal 







2004 Ability of the clinician and patient to predict the outcome 





2012 Abortion pills: Under whose control? Not relevant data 
Schaff, Ea 
(151) 
1996 Methotrexate and misoprostol for early abortion Not relevant data 
Schaff, Eric 
A (36) 
1997 Vaginal misoprostol administered at home after 





2000 Low-dose mifepristone followed by vaginal misoprostol at 





2000 Vaginal misoprostol administered 1, 2, or 3 days after 





2001 Randomized trial of oral versus vaginal misoprostol at one 
day after mifepristone for early medical abortion 










2015 Can semi-quantitative pregnancy tests assist women 















2015 Use of a semiquantitative pregnancy test (SQPT) for 





1998 Early pregnancy termination with mifepristone and 
























2010 Feasibility, efficacy, safety, and acceptability of 
mifepristone–misoprostol for medical abortion in the 











2012 Use of Medicines Changing the Face of Abortion Study review 
paper 
 
3.2 Studies and publications from ClinicalTrials.Gov (Including ongoing studies) 
Title Status Publications Reasons for exclusion 
Self-Assessment of Medical 
Abortion Outcome Using 





Not applicable Cannot screen for inclusion 
Use of Low Sensitivity 
Pregnancy Test for Self-
assessment of Medical 
Abortion (165) 
Completed  Cannot find a 
publication 
Cannot screen for inclusion 
Effectiveness of Pregnancy 
Tests as an Assessment Tool 
Completed Cannot find a 
publication 




to Identify Continuing 
Pregnancy (166) 







Not applicable Cannot screen for inclusion 
Exploring the Role of At-
home Semi-Quantitative 
Pregnancy Tests for Medical 





i) Dabash, R, 2016 (91) 
 
ii) Lynd, K., 2013 (128) 
i) Not relevant population 
 
ii) Not relevant intervention 
Effectiveness of Two 
Regimens of Misoprostol 
Alone for Early Pregnancy 
Termination and Use of 
SQPT for At-Home Follow-
Up (169) 
Completed:  Cannot find a 
publication 
Cannot screen for inclusion 
Simplifying First Trimester 






Not applicable  Cannot screen for inclusion 
Comparison of Telephone 
Follow-up With In-person 






i) Perriera, Lisa, K, 
2010 (147) 
 
ii) Clark, Wesley, 2007 
(80) 
 
iii) Clark, Wesley, 2010 
(172) 
 
iv) Kaneshiro, Bliss, 
2011 (118) 
 
v) Fiala, Christian, 
2003 (95) 
 
vi) Creinin, Mitchell D, 
1996 (89) 
 
vii) Hertzen, Helena, 
2003(112) 
 
viii) Schaff, Eric A, 
2001 (152) 
i) Not relevant study design 
 
ii) Not relevant intervention 
and study design 
 
iii) Not relevant intervention 
 
iv) Not relevant intervention 
and comparison group 
 
v) Not relevant intervention 
and outcome 
 
vi) Not relevant intervention 
 
vii) Not relevant data 
 






ix) Rossi, Brooke, 2004 
(149) 
ix) Not relevant intervention 
Simplified Medical Abortion 
in Rural India (173) 
Completed i) Paul, Mandira, 2016 
(174) 
 
ii) Paul, M, 2014 (144) 
i) Not relevant data 
 
ii) Study protocol 
Urine Pregnancy Test 










Completed i) Clark, Wesley, 
2010(172) 
 
ii) Taipale, Pekka, 2001 
(177) 
 
iii) Savitz, David A, 
2002 (178) 
 
iv) Mongelli, Max, 
1996 (179) 
 
v) Fielding, Stephen L, 
2002 (180) 
 
vi) Barnhart, Kurt T, 
1999 (181) 
 
vii) Fiala, Christian, 
2003 (95) 
i) Not relevant intervention 
 
ii) Not relevant data  
 
iii) Not relevant data  
 
iv) Not relevant data  
 
v) Not relevant data  
 
vi) Not relevant data  
 
vii) Not relevant 
intervention and comparison 
group 
Study of the Sensitivity of 
Manual vs Electric Aspiration 









Appendix 4: Characteristics of the included studies 
 
4.1 Iyengar et.al. 2015 (14) 
Characteristics of included study [Iyengar et. al., 2015] (14) 
 
Methods Study Design: Randomized, controlled, non-inferiority, trial 
Study Period: April 23, 2013 to May 15, 2014 
Study Area: Three rural and three urban health centres in 
two districts of Rajasthan state in India 
Participants Women above 18 years with unwanted pregnancies opting 
for medical abortion with gestational age 9 weeks or less 
Interventions -Instruction to women about how to perform test and 
method of follow-up given by clinicians 
-Self-assessment of outcome at home with a low sensitivity 
urine pregnancy test and pictorial instruction sheet 
-Follow-up after 2 weeks by home visit or telephone call 
Comparison -Assessment of outcome by doctors or nurses with a low 
sensitivity urine pregnancy test 
-Routine clinic follow up  
Outcomes Primary Outcome: Complete abortion without continuing 
pregnancy or need for surgical evacuation or additional 
mifepristone and misoprostol 
Secondary Outcomes: Safety (no adverse events and side 
effects) and feasibility of home assessment 
Others -N=731 (randomly assigned) 
-Mean Age: 27.1 years 
-Level of Education: 
 No formal Education: 55% 
 Primary or lower than primary: 33% 
 Secondary or above: 12% 
-Gestational age at termination: Less than 6 weeks to 9 
weeks 
-ToP Protocol: 200 mg mifepristone (taken orally at clinic) 
+ 800 mcg misoprostol (taken at home 2 days later; routes 
differed across clinics-sublingual, vaginal, or oral) 
Notes Study was conducted in a low-resource setting where half of 
the participants were illiterate and did not own a telephone. 
Risk of Bias (RoB) Assessment 
Item Author’s 
Judgement 






Quote: “Randomisation was done with a 
computer-generated randomisation sequence, 





Quote: “…we detected that 15 women in the 
clinic follow-up as per randomization list were 
allocated to the home assessment group…” 
 
Comment: It was because of an error in 
randomization by research assistants. 
However, it did not show any significant 
differences in characteristics or outcomes. 
Allocation Concealment 
(Selection Bias) 
Low Risk Quote: “Sealed opaque envelopes...” 
 




It was not possible to blind the participants. 
The biological outcomes (effectiveness and 
safety) were not likely to be influenced by 
lack of blinding of participants. However, self-
reporting (acceptability) might be influenced 
by lack of blinding. 
Blinding Personnel 
(Performance Bias) 
Low Risk Quote: “Blinding …was not possible” 
 
Comment: It was not possible to blind the 
personnel because they were involved in 
giving the instruction to women about the 
follow-up method. However, none of the 
outcomes- biological (effectiveness and 
safety) and self-reporting (acceptability) were 
likely to be influenced by lack of blinding.  




Low Risk It was not possible to blind the outcome 
assessors (women themselves in the self-
assessment group and clinicians in the clinic 
follow-up group). However, the measurement 
of effectiveness of the follow-up methods was 
not likely to be influenced by lack of blinding. 
 
Furthermore, clinicians counsel the women in 
home assessment group about how to interpret 
the test, advised to use a pictorial instruction 
sheet and seek care for complications. The test 
used was easy to interpret. Also, the 
interpretations of the results by women were 
cross-checked by research assistants by 
telephone follow-up or home visit. 
 




Low Risk It was not possible to blind the outcome 
assessors. However, the measurement of 
safety of the follow-up methods was not likely 
to be influenced by lack of blinding. 






It was not possible to blind the outcome 
assessors, especially in the case of self-




acceptability of the follow-up methods might 
be influenced by lack of blinding.  
Incomplete Outcome Data 
(Attrition Bias) 
Low Risk Loss to follow-up was very low, only around 
2.5% in the whole study. Also, there was not 
much difference in numbers across 
intervention groups (11 in clinic follow-up and 




Low Risk Quote: “The study protocol and trial is 
reported according to CONSORT 
guidelines…” 
 
Comment: The published reports included all 
the expected outcomes, including those that 
were pre-specified in the protocol (184)  
[Outcomes published in two different reports: 
 Effectiveness and Safety Outcomes-
Iyengar 2015 (14) 
 Acceptability Outcomes-Paul 2015 
(48)] 
Other Bias Low Risk No other bias detected 
 
4.2 Oppegaard et.al., 2015 (13) 
Characteristics of included study [Oppegaard et. al., 2015] (13) 
 
Methods Study Design: Randomized, controlled, non-inferiority, trial 
Study Period: August 16, 2011 to Jan 31, 2013 
Study Area: Four clinics in Austria, Finland, Norway and 
Sweden 
Participants Women aged 18 years and above who requested medical 
termination of pregnancy up to 63 days of gestational age 
Interventions - Instruction to women about how to perform test and 
method of follow-up given by clinicians 
-Self-assessment of outcome at home with a semi-
quantitative urine human chorionic gonadotropin (hCG) test 
(Two step urine hCG DUO test with two detection 
thresholds of 5 and 1000 IU/L) 
-Follow-up after 1-3 weeks by telephone consultation 
Comparison - Assessment of outcome by clinicians with a low sensitivity 
urine hCG test, measurement of hCG in serum, or 
ultrasonography 




Outcomes Primary Outcome: Complete abortion not requiring further 
medical or surgical intervention within 3 months to 
complete abortion 
Secondary Outcomes: Clinical efficacy (adverse events and 
complications, loss to follow-up, additional visits, additional 
telephone consultations, acceptability, and initiation of 
agreed contraception 
Others -N=929 (randomly assigned) 
-Mean Age: 25.97 years 
-Level of Education: Not stated 
-Mean Parity: 0.8 
-ToP Protocol: 200 mg mifepristone (taken immediately at 
clinic) + 800 µg misoprostol (taken by vaginal self-
administration at home 24-48 hours later) 
Notes - 
Risk of Bias (RoB)Assessment 
Item Author’s 
Judgement 




Low Risk Quote: “…randomisation numbers, generated 
by computer in blocks of ten.” 
Allocation Concealment 
(Selection Bias) 
Low Risk Quote: “….opening sealed, opaque, 
sequentially numbered envelopes...” 





 It was not stated in the article. However, it 
was also difficult to blind the participants in 
the given context. 
 
The biological outcomes (effectiveness and 
safety) were not likely to be influenced by 
lack of blinding of participants. However, 
self-reporting (acceptability) might be 
influenced by lack of blinding. 
Blinding of Personnel 
(Performance Bias) 
Low Risk  It was not stated in the article. However, it 
was not possible to blind the personnel as they 
were involved in giving the instruction to 
women about the follow-up method. 
Nevertheless, none of the outcomes- 
biological (effectiveness and safety) and self-
reporting (acceptability) were likely to be 










It was not stated in the article. However, it 
was not possible to blind the outcome 
assessors (women themselves in the self-
assessment group and clinicians in the clinic 
follow-up group). Nevertheless, the 
measurement of effectiveness of the follow-up 
methods was not likely to be influenced by 
lack of blinding. 




Low Risk It was not stated in the article. However, it 
was not possible to blind the outcome 
assessors. Nevertheless, the measurement of 
safety of the follow-up methods was not likely 
to be influenced by lack of blinding. 






It was not stated in the article. However, it 
was not possible to blind the outcome 
assessors, especially in the case of self-
reporting of outcome. The measurement of 
acceptability of the follow-up methods might 
be influenced by lack of blinding.  
Incomplete Outcome Data 
(Attrition Bias) 
Low Risk  108 (23%) women in the routine follow-up 
group and 90 (20%) in the self-assessment 
group were lost to follow-up. This means loss 
to follow-up was quite high in number; 
however, it was not significantly (p= 0.199) 
different between the two groups and also 
around the assumed loss to follow-up rate.  
 
Further, loss to follow-up for primary 
outcome was reduced to 0.4%. 
 
Additionally, the analysis was per protocol 
and by intention to treat, which is the 




Low Risk Comment: The published report included all 
the expected outcomes, including those that 
were pre-specified in the protocol (185). 
 





4.3 Ngoc et.al., 2014 (47) 
Characteristics of included study [Ngoc et. al., 2014] (47) 
 
Methods Study Design: Randomized controlled trial 
Study Period: May 26, 2010 to April 14, 2011 
Study Area: Four hospitals in Vietnam 
Participants Women opting for early medical abortion with gestational 
age 63 days or less 
Interventions - Instruction to women about how to perform test and 
method of follow-up given by nurses 
-Self-assessment of outcome at home with a semi-
quantitative urine pregnancy test in combination with self-
administered checklist 
-Follow-up after 2 weeks by telephone call  
Comparison -Assessment of outcome by clinicians by bimanual 
examination and transvaginal ultrasonography 
-Routine clinic follow up 
Outcomes Primary Outcome: Complete abortion without surgical 
evacuation. 
Secondary Outcomes: Acceptability of phone follow-up 
Others -N=1433 (randomly assigned) 
-Mean Age: 27 years 
-Level of Education: 
 No formal Education: 0.05% 
 Primary or lower than primary: 2.15% 
 Secondary or above: 97.8% 
-ToP Protocol: 200 mg mifepristone (taken orally at clinic) 
+ 800 micrograms misoprostol (buccal administration at 
home 24-48 hours later) 
Notes - 
Risk of Bias (RoB) Assessment 
Item Author’s 
Judgement 




Low Risk Quote: “Randomisation stratified by study site 
using random blocks of eight…” 
Allocation Concealment 
(Selection Bias) 










It was not stated in the article. However, it 
was also difficult to blind the participants in 
the given context. 
 
The biological outcomes (effectiveness and 
safety) were not likely to be influenced by 
lack of blinding of participants. However, 
self-reporting (acceptability) might be 
influenced by lack of blinding. 
Blinding of Personnel 
(Performance Bias) 
Low Risk It was not stated in the article. However, it 
was not possible to blind the personnel as they 
were involved in giving the instruction to 
women about the follow-up method. 
Nevertheless, none of the outcomes- 
biological (effectiveness and safety) and self-
reporting (acceptability) were likely to be 
influenced by lack of blinding. 






It was not stated in the article. However, it 
was not possible to blind the outcome 
assessors (women themselves in the self-
assessment group and clinicians in the clinic 
follow-up group). Nevertheless, the 
measurement of effectiveness of the follow-up 
methods was not likely to be influenced by 
lack of blinding. 




Low Risk It was not stated in the article. However, it 
was not possible to blind the outcome 
assessors. Nevertheless, the measurement of 
safety of the follow-up methods was not likely 
to be influenced by lack of blinding. 






It was not stated in the article. However, it 
was not possible to blind the outcome 
assessors, especially in the case of self-
reporting of outcome. The measurement of 
acceptability of the follow-up methods might 
be influenced by lack of blinding. 




4 women (0.6%) in phone follow-up group 
and 58 (8.1%) women in clinic follow-up 





The difference between the proportions of 
women who were loss to follow up was 
statistically significant in the two groups. 
However, the percentage of loss to follow-up 
was not high 
Selective Reporting 
(Reporting Bias) 
Low Risk The published report included all the expected 
outcomes, including those that were pre-
specified in the protocol. 
Other Bias Low Risk No other bias detected 
 
4.4 Platais et.al., 2015 (49) 
Characteristics of included study [Platais et. al., 2015] (49) 
 
Methods Study Design: Randomized controlled trial (Prospective, 
non-blinded) 
Study Period: July, 2010 to November, 2012 
Study Area: Four clinics in Moldova and three clinics in 
Uzbekistan 
Participants Women with pregnancies less than or equal to 63 days of 
gestational age who wanted a medical abortion 
Interventions - Instruction to women about how to use the test kit and 
method of follow-up given by clinicians 
-Self-assessment of outcome at home with a semi-
quantitative pregnancy test in combination with symptom 
checklist 
-Follow-up after 2 weeks by telephone call 
Comparison - Assessment of outcome by clinicians by clinical 
examination, women’s report of symptoms and ultrasound 
-Routine clinic follow up 
Outcomes Primary Outcome: Complete abortion without surgical 
evacuation 
Secondary Outcomes: Acceptability of phone follow-up 
Others -N=2400 (randomly assigned) 
-Median Age: 27 years 
-Level of Education: 
 No formal Education: 0% 
 Primary or lower than primary: 2.5% 
 Secondary or above: 97.5% 




-Median parity: 1.0 
-ToP Protocol: 200 mg mifepristone (taken orally at clinic) 
+ 400 micrograms misoprostol (sublingual administration at 
home 24-48 hours later) 
Notes - 
Risk of Bias (RoB) Assessment 
Item Author’s 
Judgement 




Low Risk Quote: “Randomisation was stratified by 
study site, using blocks of eight…” 
Allocation Concealment 
(Selection Bias) 
Low Risk Quote: “…opening sealed opaque envelopes.” 
 






Comment: It was a non-blinded trial. 
However, the biological outcomes 
(effectiveness and safety) were not likely to 
be influenced by lack of blinding of 
participants. Nevertheless, self-reporting 
(acceptability) might be influenced by lack of 
blinding. 
Blinding of Personnel 
(Performance Bias) 
Low Risk It was not possible to blind the personnel as 
they were involved in giving the instruction to 
women about the follow-up method. 
However, none of the outcomes- biological 
(effectiveness and safety) and self-reporting 
(acceptability) were likely to be influenced by 
lack of blinding. 




Low Risk It was not possible to blind the outcome 
assessors (women themselves in the self-
assessment group and clinicians in the clinic 
follow-up group). However, the measurement 
of effectiveness of the follow-up methods was 
not likely to be influenced by lack of blinding. 




Low Risk It was not possible to blind the outcome 
assessors. However, the measurement of 
safety of the follow-up methods was not likely 










It was not possible to blind the outcome 
assessors, especially in the case of self-
reporting of outcome. The measurement of 
acceptability of the follow-up methods might 
be influenced by lack of blinding. 
Incomplete Outcome Data 
(Attrition Bias) 
Low Risk  Loss to follow-up was very low (only one in 
phone follow-up group)  
Selective Reporting 
(Reporting Bias) 
Low Risk The published report included all the expected 
outcomes, including those that were pre-
specified in the protocol 





Appendix 5: GRADE evidence profile 
 
5.1 GRADE summary for primary outcome  


















































































5.1 GRADE summary for secondary outcomes 































































1 more)  
⨁⨁⨁◯ 
MODERATE  



























2 more)  
⨁⨁◯◯ 
LOW  


























5 more)  
⨁⨁◯◯ 
LOW  

























3 more)  
⨁⨁⨁◯ 
MODERATE  
CI: Confidence interval; RR: Risk ratio 
a. Somewhat wide CI, the total sample size and the no. of events are low.  
b. Heterogeneity is moderate  
c. CI is wide. Additionally, the total sample size and no. of events are low.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
